Valuation: Prostatype Genomics AB

Market Cap 60.21M 6.37M 5.46M 5.1M 4.68M 8.8M 609M 8.95M 23.58M 305M 23.92M 23.4M 1.01B P/E 2024
-0.38x
P/E 2025 -0.23x
Enterprise Value 56.44M 5.97M 5.12M 4.78M 4.39M 8.25M 571M 8.39M 22.1M 286M 22.42M 21.93M 946M EV / Sales 2024
33.9x
EV / Sales 2025 23.6x
Free-Float
99.68%
Yield 2024 *
-
Yield 2025 -
1 day+3.37%
1 week+9.25%
Current month-32.81%
1 month-40.77%
3 months-84.60%
6 months-91.70%
Current year-64.17%
1 week 0.09
Extreme 0.0932
0.11
1 month 0.09
Extreme 0.0912
0.27
Current year 0.09
Extreme 0.0912
2.28
1 year 0.09
Extreme 0.0912
2.28
3 years 0.09
Extreme 0.0912
365
5 years 0.09
Extreme 0.0912
17,940
10 years 0.09
Extreme 0.0912
18,400
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Director of Finance/CFO - 2023-10-30
General Counsel - 2023-02-28
Director TitleAgeSince
Chairman - 2016-12-31
Director/Board Member - 2017-12-31
Director/Board Member 74 2018-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+3.37%+9.25%-82.14%-99.97% 6.11M
+4.29%+2.88%+103.02%+518.00% 44.93B
+2.56%+2.15%+19.82%+54.10% 26.13B
-7.47%-2.68%-24.15%-32.40% 8.07B
+2.32%-1.83%+11.20%+154.09% 5.81B
-0.75%-3.38%+11.46%+68.35% 3.32B
+4.34%-3.33%-33.98%+1,542.27% 2.28B
+4.75%+1.43%+163.95%+22.92% 2.04B
-3.39%-7.63%-9.01%-55.68% 1.99B
+0.16%+0.16%+30.95%+20.42% 1.88B
Average +1.02%-1.19%+19.11%+219.21% 9.64B
Weighted average by Cap. +2.32%+1.44%+55.49%+301.02%

Financials

2024 2025
Net sales 1.92M 203K 174K 163K 149K 280K 19.4M 285K 751K 9.73M 762K 745K 32.16M 594K 62.85K 53.91K 50.34K 46.19K 86.85K 6.01M 88.28K 233K 3.01M 236K 231K 9.96M
Net income -41.05M -4.34M -3.73M -3.48M -3.19M -6M -415M -6.1M -16.07M -208M -16.31M -15.95M -688M -44.5M -4.71M -4.04M -3.77M -3.46M -6.51M -450M -6.61M -17.43M -226M -17.68M -17.29M -746M
Net Debt -9.35M -990K -849K -793K -727K -1.37M -94.58M -1.39M -3.66M -47.44M -3.72M -3.63M -157M -3.77M -399K -342K -319K -293K -551K -38.1M -560K -1.48M -19.11M -1.5M -1.46M -63.19M
Logo Prostatype Genomics AB
Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Employees
7
Date Price Change Volume
26-08-19 SEK 0.1075 +3.37% 3,478,433
26-08-18 SEK 0.1040 +1.96% 5,509,835
26-08-17 SEK 0.1020 +4.08% 17,368,074
26-08-14 SEK 0.0980 +1.03% 6,926,800
26-08-13 SEK 0.0970 -1.42% 10,913,288
  1. Stock Market
  2. Stocks
  3. PROGEN Stock